Cargando…

SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma()()

Multiple myeloma (MM), a hematological malignancy characterized by the clonal growth of malignant plasma cells (PCs) in the bone marrow, is preceded by the benign asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS). Several genetic abnormalities have been identified as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noll, Jacqueline E., Hewett, Duncan R., Williams, Sharon A., Vandyke, Kate, Kok, Chung, To, Luen B., Zannettino, Andrew C.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198825/ https://www.ncbi.nlm.nih.gov/pubmed/25117979 http://dx.doi.org/10.1016/j.neo.2014.07.002

Ejemplares similares

Characterization of the role of Samsn1 loss in multiple myeloma development
por: Friend, Natasha L., et al.
Publicado: (2020)

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
por: Noll, Jacqueline E., et al.
Publicado: (2015)

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice
por: Friend, Natasha, et al.
Publicado: (2020)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
por: Opperman, Khatora S., et al.
Publicado: (2019)

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment
por: Hewett, Duncan R., et al.
Publicado: (2017)

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo
por: Zeissig, Mara N., et al.
Publicado: (2020)

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib
por: Mrozik, Krzysztof M., et al.
Publicado: (2020)

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma
por: Zeissig, Mara N., et al.
Publicado: (2020)

Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo
por: Clark, Kimberley C., et al.
Publicado: (2020)

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
por: Dutta, Ankit K., et al.
Publicado: (2018)

SAMSN1 Is Highly Expressed and Associated with a Poor Survival in Glioblastoma Multiforme
por: Yan, Yong, et al.
Publicado: (2013)

Macrophage SAMSN1 protects against sepsis-induced acute lung injury in mice
por: Jiang, Wanli, et al.
Publicado: (2022)

Using genomics to better define high-risk MGUS/SMM patients
por: Dutta, Ankit K., et al.
Publicado: (2018)

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
por: Ebert, Lisa M., et al.
Publicado: (2021)

Suppression of SAMSN1 contributes to neuroprotection in neonatal rats suffering from hypoxic–ischemic encephalopathy injury
por: Wang, Yi‐Bo, et al.
Publicado: (2022)

Lama2 And Samsn1 Mediate the Effects of Brn4 on Hippocampal Neural Stem Cell Proliferation and Differentiation
por: Zhang, Lei, et al.
Publicado: (2023)

Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma
por: Bradey, Alanah L., et al.
Publicado: (2022)

Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
por: Noll, J E, et al.
Publicado: (2012)

Frequent Down Regulation of the Tumor Suppressor Gene A20 in Multiple Myeloma
por: Troppan, Katharina, et al.
Publicado: (2015)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
por: Mrozik, Krzysztof Marek, et al.
Publicado: (2018)

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma
por: Liu, Yang, et al.
Publicado: (2013)

Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis
por: Abdi, Jahangir, et al.
Publicado: (2017)

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma
por: Wang, Yafei, et al.
Publicado: (2022)

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
por: Giannotta, Claudia, et al.
Publicado: (2023)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma
por: Binsfeld, Marilène, et al.
Publicado: (2016)

Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells
por: ZHOU, WENWEN, et al.
Publicado: (2014)

Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population
por: Karabon, Lidia, et al.
Publicado: (2011)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity
por: Petersson, Julia, et al.
Publicado: (2021)

The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma
por: Mroczek, Seweryn, et al.
Publicado: (2017)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Quantitative Methylation Profiles for Multiple Tumor Suppressor Gene Promoters in Salivary Gland Tumors
por: Durr, Megan L., et al.
Publicado: (2010)

Nonsecretory Multiple Myeloma Presenting as an Intestinal Tumor
por: Triantafyllopoulou, Diana, et al.
Publicado: (2015)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjob01a70f88n6vpkt7th5pgdb